What is the function of clofazimine soft capsules? Full analysis of clinical uses

Clofazimine (Clofazimine) is an anti-leprosy drug with dual antibacterial and anti-inflammatory effects. It is a phenazine fat-soluble dye. It was first developed by the Swiss company Ciba-Geigy and is currently listed by the World Health Organization as one of the core drugs in the leprosy multidrug treatment program (MDT), especially for the long-term treatment of patients with multibacillary leprosy (MB). Its mechanism of action has not yet been fully elucidated, but studies have shown that clofazimine can interfere with the DNA replication process of mycobacteria, and has the ability to regulate immune responses, reduce macrophage endocytosis, and inhibit the release of inflammatory factors.

In clinical practice, clofazimine is mainly used in the following situations: First, it is combined with rifampin and dapsone to treat leprosy to enhance the efficacy and reduce the incidence of drug resistance; second, it is used as an anti-inflammatory agent for leprosy reactions (especiallyType II reactions, that is, erythema nodosum) The drug replaces or supplements the use of glucocorticoids to reduce acute inflammatory manifestations such as skin nodules, joint pain and fever; third, it is used for non-tuberculous mycobacteria (NTM) infections, such as pulmonary or disseminated infections caused by Mycobacterium avium complex (MAC), and is especially suitable for cases that are resistant to conventional antibiotics. In addition, clofazimine has also been explored in recent years for the treatment of new pathogenic infections and inflammatory diseases, such as infections with drug-resistant strains of Mycobacterium tuberculosis or the control of certain chronic immune-mediated diseases.

Clofazimine is a prescription drug. The common dosage form is50mg or 100mg soft capsules. After oral administration, it needs to be taken with food to enhance absorption. During long-term use, common adverse reactions include discoloration of skin and body fluids, gastrointestinal discomfort (such as abdominal pain, nausea, loss of appetite) and rare intestinal crystal deposition. Its advantage is that it has a long half-life and is suitable for maintenance treatment of chronic diseases, but it is not suitable for short-term use to avoid accumulation. Due to its complex pharmacokinetics and possible interactions with other antibacterial drugs, patients must strictly follow medical instructions during use and regularly follow up on liver and kidney function, blood routine, and symptom changes.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine